Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

Share Price is delayed by 15 minutes
Get Live Data
103.20    -5.80 (-5.32%)
Bid:
103.00
Ask:
104.20
Spread: 1.20 (1.165%)
Market Cap: £169.19m
SYNT Live PriceLast checked at - London Stock Exchange

Intraday Synthomer Share Chart

Quarter 1 Trading Update

30 Apr 2015 07:00

RNS Number : 7698L
Synthomer PLC
30 April 2015
 

April 30th 2015

Synthomer plc

Quarter 1 trading update

Synthomer plc ('Synthomer' or 'the Group') today issues a trading update for the first quarter ended March 31 2015.

Trading

Trading in the first quarter has been in line with the Board's expectations at the time of the full year 2014 results.

In our European and North American (ENA) business, volumes were slightly below the same period in 2014, where we experienced a good start to the year. We saw some modest margin benefit from declining raw material prices, and constant currency operating profit was slightly ahead of the prior year but behind on a reported basis, due to the weakness of the Euro.

We reported with our full year 2014 results that unit margins in our Asian nitrile business had firmed through the second half and demand had strengthened through the fourth quarter. Demand has remained strong through the first quarter of 2015 and we have seen a further improvement in margins. Consequently, our operating profit in our Asia and Rest of the World (ARW) segment was substantially ahead of the prior year.

The Group is currently developing plans for a further expansion of its nitrile latex capacity, and expects to make an announcement in the next few months.

Financial Position

Capital expenditure was low in the quarter, and the seasonal outflow of working capital was lower than usual, due to the impact of falling input costs. Together with the translation effect on euro denominated debt, this resulted in a reduction of net debt from the year end to below £100 million (December 2014 £112M million).

The Board announced at the time of the full year 2014 results that in line with its capital management policy, a special dividend of 7.8p per share, equivalent to £26.5 million which will be paid in July, along with the normal final dividend from 2014 of 4.8p per share.

Outlook

Europe is expected to remain challenging due to both the general economic environment and ongoing currency effects. In Asia we expect to continue to perform strongly due to the current demand and margin trends in nitrile. The Board remains confident in the medium and long term growth prospects for the Group.

Synthomer will announce its Interim Results on Tuesday 11th August 2015.

Enquiries:

 

Calum MacLean, Chief Executive Officer

Charles Armitstead

David Blackwood, Chief Financial Officer

Pendomer

Tel: 01279 775220

Tel: 020 3603 5220

 

The Company will host a conference call for analysts at 8.00am (BST) today:

 

Dial-In: +44 (0)203 427 0662

Please quote "Synthomer" to gain access to the call

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTZMGZDNLRGKZM
Date   Source Headline
1st Jun 20262:42 pmRNSHolding(s) in Company
29th May 20263:57 pmRNSTotal Voting Rights
22nd May 20265:21 pmRNSNotice of AGM
8th May 20264:33 pmRNSAdmission to Trading
7th May 20261:51 pmRNSApplication for Admission to Trading
5th May 20264:25 pmRNSHolding(s) in Company
30th Apr 20264:40 pmRNSAnnual Financial Report
30th Apr 20263:17 pmRNSDirector/PDMR Shareholding
30th Apr 202611:25 amRNSDirector/PDMR Shareholding
30th Apr 20267:01 amRNSChange of Chief Financial Officer
30th Apr 20267:00 amRNSFinal Results
19th Mar 20267:00 amRNSTrading and refinancing update
11th Feb 20261:46 pmRNSStatement re potential refinancing
29th Jan 20267:00 amRNSTrading Statement - Winter 2026
27th Jan 20264:51 pmRNSHolding(s) in Company
26th Jan 20264:23 pmRNSHolding(s) in Company
18th Dec 20257:00 amRNSReceivables purchasing arrangement
12th Dec 20259:30 amRNSDirectorate change
12th Nov 20257:00 amRNSDirector/PDMR Shareholding
5th Nov 20251:28 pmRNSHolding(s) in Company
23rd Oct 20257:00 amRNSTrading statement - Autumn 2025
14th Oct 20257:00 amRNSAppointment of joint corporate broker
4th Sep 20255:17 pmRNSHolding(s) in Company
11th Aug 20258:00 amRNSDirector/PDMR Shareholding
6th Aug 20259:45 amRNSDirector/PDMR Shareholding
5th Aug 202511:57 amRNSDirector/PDMR Shareholding
5th Aug 202511:00 amRNSDirectorate Change
5th Aug 20257:00 amRNSInterim results
4th Jul 20257:01 amRNSDirector/PDMR Shareholding
1st Jul 20257:00 amRNSCovenant update
30th Jun 20257:00 amRNSDirectorate Changes
27th Jun 20254:21 pmRNSHolding(s) in Company
2nd Jun 20257:00 amRNSDivestment of William Blythe completed
6th May 20257:00 amRNSDivestment of William Blythe
1st May 20254:18 pmRNSResults of AGM
1st May 20257:00 amRNSTrading Statement - Spring 2025
15th Apr 20253:00 pmRNSHolding(s) in Company
28th Mar 20257:30 amRNSDirector/PDMR Shareholding
27th Mar 20257:30 amRNSDirector/PDMR Shareholding
25th Mar 20254:23 pmRNSAnnual Report and Notice of AGM
25th Mar 202511:43 amRNSDirector/PDMR Shareholding
25th Mar 202511:41 amRNSDirector/PDMR Shareholding
24th Mar 20257:30 amRNSHolding(s) in Company
17th Mar 20259:00 amRNSDirector/PDMR Shareholding
17th Mar 20259:00 amRNSDirector/PDMR Shareholding
11th Mar 20257:00 amRNSFinal Results
6th Mar 20258:32 amRNSDirector Declaration
13th Feb 20257:00 amRNSHolding(s) in Company
28th Jan 202510:30 amRNSDirector/PDMR Shareholding
28th Jan 20257:00 amRNSWinter trading statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.